Hypera (OTCMKTS:HYPMY - Get Free Report) issued its earnings results on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter, Zacks reports. Hypera had a net margin of 20.04% and a return on equity of 13.18%. The firm had revenue of $258.56 million during the quarter.
Hypera Stock Performance
Shares of HYPMY stock traded up $0.16 on Wednesday, hitting $3.51. The company had a trading volume of 424 shares, compared to its average volume of 8,591. Hypera has a twelve month low of $2.64 and a twelve month high of $6.83. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.68. The firm has a market cap of $2.22 billion, a P/E ratio of 8.78 and a beta of 0.99. The company has a 50-day moving average price of $3.29 and a 200-day moving average price of $3.70.
Hypera Company Profile
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Featured Articles
Before you consider Hypera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypera wasn't on the list.
While Hypera currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
